Avrobio Inc (AVRO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Geoff MacKay
Employees:
120
ONE KENDALL SQUARE, BLDG. 300, SUITE 201, CAMBRIDGE, MA 02139
7819626030

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies. Its product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 48.503 Million Shares Outstanding43.696 Million Avg 30-day Volume 218.177 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.75
Price to Revenue0.0 Debt to Equity0.1049 EBITDA-119.949 Million
Price to Book Value0.4029 Operating Margin0.0 Enterprise Value-88.964 Million
Current Ratio9.978 EPS Growth0.119 Quick Ratio9.437
1 Yr BETA 1.4345 52-week High/Low 6.88 / 0.74 Profit Margin0.0
Operating Cash Flow Growth4.8289 Altman Z-Score-3.4584 Free Cash Flow to Firm -81.58 Million
Earnings Report2022-11-03
View SEC Filings from AVRO instead.

View recent insider trading info

Funds Holding AVRO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVRO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-24:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-18:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-17:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-17:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-07:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DONENBERG PHILLIP B.

    • Director
    34,956 2022-06-08 1

    CLARK IAN T

    • Director
    34,956 2022-06-08 1

    BOOTH BRUCE

    • Director
    34,956 2022-06-08 1

    FARFEL GAIL M

    • Director
    34,956 2022-06-08 1

    VICKERS PHILIP J.

    • Director
    34,956 2022-06-08 1

    JENKINS ANNALISA

    • Director
    34,956 2022-06-08 1

    PAIGE CHRISTOPHER

    • Director
    34,956 2022-06-08 1

    GOLIPOUR AZADEH CHIEF TECHNOLOGY OFFICER

    • Officer
    36,344 2022-06-08 1

    PETERSEN DEANNA M CHIEF BUSINESS OFFICER

    • Officer
    180,000 2022-02-02 1

    MACKAY GEOFFREY PRESIDENT & CEO

    • Officer
    • Director
    733,500 2022-02-02 1

    AVRUCH STEVEN CHIEF LEGAL OFFICER

    • Officer
    195,000 2022-02-02 1

    OSTROWSKI ERIK CHIEF FINANCIAL OFFICER

    • Officer
    315,000 2022-02-02 1

    RIDHA ESSRA CHIEF MEDICAL OFFICER

    • Officer
    155,000 2022-02-02 3

    ESCOLAR DIANA CHIEF MEDICAL OFFICER

    • Officer
    50,000 2021-06-10 0

    MASON CHRISTOPHER CHIEF SCIENTIFIC OFFICER

    • Officer
    125,000 2021-06-10 0

    VOLCK BIRGITTE PRESIDENT OF R&D

    • Officer
    0 2020-03-04 0

    ATLAS VENTURE ASSOCIATES X, L.P.

    • 10% Owner
    3,710,052 2020-02-13 0

    ATLAS VENTURE FUND X, L.P.

    ATLAS VENTURE ASSOCIATES X, L.P.

    ATLAS VENTURE ASSOCIATES X, LLC

    • 10% Owner
    5,567,289 2019-07-19 0

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

    • SEE REMARKSSEE REMARKSSEE REMARKS
    810,811 2019-07-19 0

    CLARUS LIFESCIENCES III, L.P.

    CLARUS VENTURES III GP, L.P.

    • 10% Owner
    No longer subject to file 2019-05-20 0

    DEEGAN GLENN E SECRETARY

    • Officer
    1,000,000 2007-03-19 0

    CODEANNE CHRISTOPHER GEORGE CHIEF FINANCIAL OFFICER

    • Officer
    0 2007-01-16 0

    SANCILIO FREDERICK D

    • Director
    250 2006-05-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AVROBIO INC AVRO 2022-08-16 22:15:05 UTC -1.3139 3.6339 900000
    AVROBIO INC AVRO 2022-08-16 21:45:03 UTC -1.3582 3.6782 900000
    AVROBIO INC AVRO 2022-08-16 21:15:03 UTC -1.3582 3.6782 900000
    AVROBIO INC AVRO 2022-08-16 20:45:05 UTC -1.4174 3.7374 900000
    AVROBIO INC AVRO 2022-08-16 20:15:04 UTC -1.4174 3.7374 900000
    AVROBIO INC AVRO 2022-08-16 19:45:04 UTC -1.4174 3.7374 900000
    AVROBIO INC AVRO 2022-08-16 19:15:05 UTC -1.4174 3.7374 900000
    AVROBIO INC AVRO 2022-08-16 18:45:04 UTC -1.4174 3.7374 900000
    AVROBIO INC AVRO 2022-08-16 18:15:05 UTC -1.4174 3.7374 900000
    AVROBIO INC AVRO 2022-08-16 17:45:04 UTC -1.4174 3.7374 900000
    AVROBIO INC AVRO 2022-08-16 17:15:04 UTC -1.4174 3.7374 900000
    AVROBIO INC AVRO 2022-08-16 16:45:04 UTC -1.9642 4.2842 900000
    AVROBIO INC AVRO 2022-08-16 16:15:04 UTC -1.9642 4.2842 900000
    AVROBIO INC AVRO 2022-08-16 15:45:04 UTC -1.9642 4.2842 900000
    AVROBIO INC AVRO 2022-08-16 15:15:03 UTC -1.9642 4.2842 900000
    AVROBIO INC AVRO 2022-08-16 14:45:03 UTC -1.9642 4.2842 850000
    AVROBIO INC AVRO 2022-08-16 14:15:04 UTC -1.9642 4.2842 850000
    AVROBIO INC AVRO 2022-08-16 13:45:05 UTC -0.5855 2.9055 500000
    AVROBIO INC AVRO 2022-08-16 13:15:04 UTC -0.5855 2.9055 500000
    AVROBIO INC AVRO 2022-08-16 12:45:03 UTC -0.5855 2.9055 500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund AVRO -58.0 shares, $-902.48 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund AVRO -3.0 shares, $-46.68 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund AVRO -34.0 shares, $-529.04 2020-03-31 N-PORT

    Elevate your investments